About
About Nanjing Hicin Pharmaceutical Co., Ltd
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company's products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for injection; voglibose tablets, lansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets; and raw materials, intermediates, and other products. Its products are used in cardiovascular and cerebrovascular, diuretic, anti-infection, digestive system, immune regulation, hypoglycemic, orthopedics, and other treatment areas. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is headquartered in Nanjing, China.
Research context
Nanjing Hicin Pharmaceutical Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Nanjing Hicin Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 6.2% below its 200 day moving average.
From a valuation standpoint, the stock is 69.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.9.
Nanjing Hicin Pharmaceutical Co., Ltd's total revenue sank by 24.8% to $172M since the same quarter in the previous year.
Its net income has dropped by 51.9% to $12M since the same quarter in the previous year.
Finally, its free cash flow grew by 180.1% to $22M since the same quarter in the previous year.
Based on the above factors, Nanjing Hicin Pharmaceutical Co., Ltd gets an overall score of 2/5.